Effectiveness and safety of vascular intervention plus lenvatinib versus vascular intervention alone for hepatocellular carcinoma patients with portal vein tumor thrombus: a retrospective comparative study

Effectiveness and safety of vascular intervention plus lenvatinib versus vascular intervention alone for hepatocellular carcinoma patients with portal vein tumor thrombus: a retrospective comparative study

BackgroundThis study aimed to assess the effectiveness and safety of vascular intervention combined with lenvatinib versus vascular intervention alone in the treatment of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT), and to identify prognostic factors associated wit...

Full description

Bibliographic Details
Main Authors:	Saikang Tang, Yingming Gao, Xue Yan, Weihua Zhi, Yue Han
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-07-01
Series:	Frontiers in Oncology
Subjects:	hepatocellular carcinoma (HCC) portal vein tumor thrombus (PVTT) transarterial chemoembolization (TACE) hepatic arterial infusion chemotherapy (HAIC) lenvatinib
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1431069/full

Similar Items

Development of a Prognostic Scoring System for Hepatocellular Carcinoma Patients With Main Portal Vein Tumor Thrombus Undergoing Conventional Transarterial Chemoembolization: An Analysis of 173 Patients
by: Jing-huan Li, et al.
Published: (2021-08-01)

The treatment of transarterial chemoembolization/hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitor is effective against hepatocellular carcinoma with portal vein tumor thrombus: A systematic review
by: Gao Yuanren, et al.
Published: (2023-03-01)

A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus
by: Xiaomi Li, et al.
Published: (2023-08-01)

Survival benefit of neoadjuvant hepatic arterial infusion chemotherapy followed by hepatectomy for hepatocellular carcinoma with portal vein tumor thrombus
by: Zili Hu, et al.
Published: (2023-09-01)

Safety and efficacy of radiotherapy combined with lenvatinib plus PD-1 inhibitors as neo-adjuvant therapy in hepatocellular carcinoma with portal vein thrombus: protocol of an open-label, single-arm, prospective, multi-center phase I trial
by: Guangxin Li, et al.
Published: (2022-11-01)

Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis
by: Jia Deng, et al.
Published: (2023-01-01)

Efficacy and safety of transarterial chemoembolization plus antiangiogenic- targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world
by: Jin-Kai Feng, et al.
Published: (2022-11-01)

Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis
by: Jun-Ning Liu, et al.
Published: (2023-02-01)

Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis
by: Jun-Ning Liu, et al.
Published: (2023-06-01)

Efficacy of radiation plus transarterial chemoembolization and lenvatinib in hepatocellular carcinoma with portal vein tumor thrombus
by: Aoran Dong, et al.
Published: (2023-12-01)

PD-1 combined with lenvatinib and TACE for the transformational treatment of hepatocellular carcinoma combined with portal vein tumor thrombus: a case report and literature review
by: Sheng Liu, et al.
Published: (2023-10-01)

Efficacy and safety of TACE combined with lenvatinib and PD‐1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study
by: Wei‐Jun Wang, et al.
Published: (2023-05-01)

Efficacy and Safety of Transarterial Chemoembolization in Elderly Patients of Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Retrospective Study
by: Qinghe Tang, et al.
Published: (2021-07-01)

Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study
by: Lingzhan Meng, et al.
Published: (2024-11-01)

Combined versus single interventional therapies in treatment of hepatic malignant tumors
by: Gihan Hassan Gamal, et al.
Published: (2014-03-01)

HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study
by: Xu Chang, et al.
Published: (2024-04-01)

Longitudinal Analysis of the Effect of Repeated Transarterial Chemoembolization for Liver Cancer on Portal Venous Pressure
by: Constantine Frangakis, et al.
Published: (2021-11-01)

Efficacy of TACE Combined with Lenvatinib Plus Sintilimab for Hepatocellular Carcinoma with Tumor Thrombus in the Inferior Vena Cava and/or Right Atrium
by: Ning S, et al.
Published: (2023-09-01)

A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma
by: Gan L, et al.
Published: (2023-04-01)

Combined iodine-125 seed strand, portal vein stent, transarterial chemoembolization, lenvatinib and anti-PD-1 antibodies therapy for hepatocellular carcinoma and Vp4 portal vein tumor thrombus: A propensity-score analysis
by: Zi-Han Zhang, et al.
Published: (2023-01-01)

Feasibility and Safety of the Clinical Outcomes of TACE Combined with Lenvatinib and PD-1 Blockades in the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Retrospective Exploratory Study
by: Sun W, et al.
Published: (2024-08-01)

Common interventional techniques (single versus combined) in management of hepatocellular carcinoma
by: Mostafa M. Shakweer, et al.
Published: (2016-12-01)

Cost-effectiveness analysis of transarterial chemoembolization combined with lenvatinib as the first-line treatment for advanced hepatocellular carcinoma
by: Ying He, et al.
Published: (2023-09-01)

Both anti-angiogenesis and immunotherapy combined with interventional therapy in treatment of hepatocellular carcinoma: effect of hepatic artery infusion chemotherapy compared with hepatic artery chemoembolization
by: ZHANG Xihao, ZHANG Xinyun, CAO Manqing, ZHANG Jinliang, WANG Huaqi, ZHANG Su, FU Zhou, WANG Lu, ZHANG Ti
Published: (2022-05-01)

Adjuvant transarterial chemoembolization timing after radical resection is an independent prognostic factor for patients with hepatocellular carcinoma
by: Hongfa Sun, et al.
Published: (2023-03-01)

Optimizing outcomes in HCC: Comment on “optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis” by Jiang et al.
by: Alessandro Rizzo
Published: (2021-12-01)

Clinical Outcomes of Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab for Treating Hepatocellular Carcinoma and Type IV Portal Vein Tumor Thrombus
by: Li X, et al.
Published: (2025-01-01)

Radiotherapy plus lenvatinib versus radiotherapy plus sorafenib for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study
by: Min Zhang, et al.
Published: (2024-10-01)

Network meta-analysis of treatment regimens for inoperable advanced hepatocellular carcinoma with portal vein invasion
by: Li MF, et al.
Published: (2018-07-01)

Survival benefit of hepatic resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis
by: Xiu-Ping Zhang, et al.
Published: (2017-12-01)

Transarterial Chemoembolization Plus Lenvatinib and PD-1 Inhibitors for Hepatocellular Carcinoma with Main Trunk Portal Vein Tumor Thrombus: A Multicenter Retrospective Study
by: Li SQ, et al.
Published: (2023-10-01)

Prognosis of patients with hepatocellular carcinoma and portal vein tumor thrombus treated with combination of transarterial chemoembolization and palliative thermal ablation
by: Qunfang Zhou, et al.
Published: (2022-12-01)

The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
by: Fangzhou Luo, et al.
Published: (2021-09-01)

Clinical analysis of deceased donor liver transplantation in the treatment of hepatocellular carcinoma with segmental portal vein tumor thrombus: A long-term real-world study
by: Meng Sha, et al.
Published: (2022-09-01)

Efficacy and safety of transarterial chemoembolization combined with lenvatinib and camrelizumab in patients with BCLC-defined stage C hepatocellular carcinoma
by: Juan Wu, et al.
Published: (2023-10-01)

BCLC-B hepatocellular carcinoma treatment or when should the systemic therapy be started
by: V. V. Breder, et al.
Published: (2018-07-01)

Efficacy of adjuvant TACE on the prognosis of patients with HCC after hepatectomy: a multicenter propensity score matching from China
by: Zhao Wu, et al.
Published: (2023-04-01)

Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma
by: Yusuke Kawamura, et al.
Published: (2020-10-01)

Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis
by: Moon Haeng Hur, et al.
Published: (2023-07-01)

Correlation and efficacy of TACE combined with lenvatinib plus PD‐1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features
by: Xinhua Zou, et al.
Published: (2023-05-01)